AllianceBernstein
GLUE icon

AllianceBernstein’s Monte Rosa Therapeutics GLUE Stock Holding History

AllianceBernstein’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Buy
87,420
+31,720
+57% +$599K ﹤0.01% 2213
2026
Q1 		$873K Sell
55,700
-7,780
-12% -$149K ﹤0.01% 2390
2025
Q4 		$995K Hold
63,480
– – ﹤0.01% 2342
2025
Q3 		$470K Hold
63,480
– – ﹤0.01% 2712
2025
Q2 		$286K Buy
63,480
+28,340
+81% +$126K ﹤0.01% 2937
2025
Q1 		$163K Hold
35,140
– – ﹤0.01% 2974
2024
Q4 		$244K Hold
35,140
– – ﹤0.01% 2970
2024
Q3 		$186K Buy
35,140
+2,360
+7% +$11.9K ﹤0.01% 3051
2024
Q2 		$123K Buy
32,780
+9,210
+39% +$47K ﹤0.01% 3096
2024
Q1 		$166K Hold
23,570
– – ﹤0.01% 2959
2023
Q4 		$133K Hold
23,570
– – ﹤0.01% 3030
2023
Q3 		$113K Buy
23,570
+1,720
+8% +$11.1K ﹤0.01% 3047
2023
Q2 		$150K Buy
21,850
+7,650
+54% +$49.5K ﹤0.01% 3032
2023
Q1 		$111K Buy
14,200
+1,800
+15% +$12.5K ﹤0.01% 3017
2022
Q4 		$94.4K Buy
+12,400
New +$103K ﹤0.01% 3117
2022
Q2 		– Sell
-81,302
Closed -$1.14M – 3310
2022
Q1 		$1.14M Sell
81,302
-8,867
-10% -$123K ﹤0.01% 2376
2021
Q4 		$1.84M Buy
90,169
+5,722
+7% +$120K ﹤0.01% 2193
2021
Q3 		$1.88M Sell
84,447
-54,648
-39% -$1.57M ﹤0.01% 2205
2021
Q2 		$3.16M Buy
+139,095
New +$2.83M ﹤0.01% 1902

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AllianceBernstein's GLUE Position: Q2 2026 in Review

AllianceBernstein increased its Monte Rosa Therapeutics (GLUE) stake by 57% in Q2 2026, buying an estimated $599K and bringing the position to 87,420 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #2213.

AllianceBernstein first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. The position peaked at $3.16M in Q2 2021. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • AllianceBernstein held 87,420 shares of Monte Rosa Therapeutics worth $1.44M as of Q2 2026.
  • AllianceBernstein bought 31,720 Monte Rosa Therapeutics shares in Q2 2026, an estimated $599K.
  • Monte Rosa Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2213 holding.
  • AllianceBernstein first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • AllianceBernstein's Monte Rosa Therapeutics position peaked at $3.16M in Q2 2021.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.